Company intelligence / Profile preview

Nihon Pharmaceutical

Ownership: Private
Development stage: Other

Overview

Nihon Pharmaceutical is a Japanese pharmaceutical company specializing in plasma-derived therapies and contract manufacturing. It has several approved products in Japan, including lyophilized human antithrombin III concentrate and human normal immunoglobulin. The company also has preclinical programs targeting myasthenia gravis and pending programs for intestinal diseases and prostate cancer. Since April 2021, it operates as a wholly owned subsidiary of Takeda.

Therapeutic areas: GastroenterologyHematologyOncologyNeurology
Modalities: Fusion proteinImmunoglobulinEnzymeSmall molecule
Industry: Pharma

Drug pipeline

2 assets

NPB-01-ME

1 more asset in the full pipeline.

Request access →

Partnerships

Takeda Group integration; previously collaborated with Takeda on plasma-derived therapies.

Beyond the preview

Go deeper on Nihon Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nihon Pharmaceutical.

Explore the full profile